

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
12 February 2004 (12.02.2004)

PCT

(10) International Publication Number
WO 2004/012718 A1

(51) International Patent Classification⁷: **A61K 9/50**, 9/20

[SE/SE]; AstraZeneca R & D Sodertalje, S-151 85 Sodertalje (SE).

(21) International Application Number:

PCT/GB2003/003195

(74) Agent: **ASTRAZENECA**; Global Intellectual Property, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(22) International Filing Date: 28 July 2003 (28.07.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0202353-9

1 August 2002 (01.08.2002) SE

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicant (*for AE, AG, AL, AM, AT, AU, AZ, BA, BB, BE, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CY, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, FR, GB, GD, GE, GH, GM, GR, HR, HU, ID, IE, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, SZ, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW only*): **ASTRAZENECA AB** [SE/SE]; Sodertalje, S-151 85 (SE).

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(71) Applicant (*for MG only*): **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, London, Greater London W1K 1LN (GB).

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): **BUZSAKY, Ferenc**

(54) Title: NEW FILM COATING

(57) Abstract: A film coating composition suitable for use in coating pharmaceutical formulations comprising: a) an acrylic polymer, which is Eudragit[®] NE30D, b) an anti-sticking agent, which is glyceryl monostearate (GMS), c) a surface active agent wherein the surface active agent is in an amount less than 1.3% by weight of the dispersion, and d) a water-containing liquid, wherein the dispersion does not contain a vinyl acetate polymer.



WO 2004/012718 A1

NEW FILM COATING

Field of the invention

5 The present invention relates to a new film coating. More specifically the present invention relates to a new film coating for the achievement of modified release from pharmaceutical formulations such as tablets, pellets, etc., wherein the film coating may be applied in a substantially aqueous environment. Furthermore, the invention provides a process for the preparation of such a film coating.

Background of the invention

10 Oral administration of a drug is the most convenient for the patient. Oral formulations must also meet the requirements of safety and simplicity. Depending on the drug properties and the therapeutic requirements, different approaches are taken during its formulation to obtain a suitable drug delivery profile. For example, a sparingly soluble drug which is given once a day requires a different type of formulation than an easily soluble drug which is taken several times a day.

20 Different formulations can have different mechanisms for controlling the release of the active drug. In the thesis by Sandberg 1994, extended-release (ER) formulations of different types of drugs were reviewed. It was concluded that in principle two types of ER dosage forms exist: (i) the matrix system where the drug is mixed with the matrix material (often a polymer or a wax) and (ii) the drug reservoir system where the drug is formulated into a core (tablet or pellets) surrounded by a polymeric film. The film coating is then a release rate-controlling barrier determined by many factors including its dissolution rate, its permeability, the solubility of the substance, etc.

30 From a flexibility point of view the formulation of a drug into small discrete units coated with a film has gained much attention. Such a formulation shows several interesting

features such as flexibility in dosage and release properties. In addition, tablets made from these discrete units are easily divisible. In a number of studies it was shown that safe, simple and convenient therapy can be achieved utilizing this principle for the (water soluble) drug metoprolol and its salts (Ragnarsson et al, *Drug Develop Ind Pharmacy* 13, 1495 (1987); Sandberg et al, *Eur J Clin Pharmacol* 33, S3 (1988) and S9 (1988); Ragnarsson et al, *Int J Pharmaceuticl* 79, 223 (1992); Sandberg et al, *Ibid* 68, 167 (1991); Sandberg et al, *Pharmaceuticl Res* 10, 28 (1993); Sandberg et al, *Drug Invest* 6, 320 (1993); Sandberg, Thesis Uppsala University, (1994).

The formulation of metoprolol into pellets according to the above mentioned references utilized a film coating sprayed from a solution containing a mixture of different celluloses in an organic solvent. However, for environmental reasons it would be preferable to use water based film-forming systems for this and other drugs to be formulated as pellets systems. Thus, much effort has been directed to find suitable water based systems for film coating in drug delivery systems.

Latex particles in water as the dispersion medium have been known for almost half a century. These particles are polymeric colloidal particles in the 10 to 100 nm range and have been utilized as film formers in different applications. If the polymer particle has a sufficiently low glass transition temperature (T_g) when the water is evaporated, the particles can coalesce to form a film. Further development has given several other products that have been tested and reported in a number of publications (Petereit and Weisbrod, *Eur J Pharmaceutics and Biopharm* 47, 15 (1999); Petereit et al, *Ibid*, 41, 219 (1995); Amighi and Moës, *STP Pharma Sci* 7, 141 (1997); Bodmeier and Paeratakul, *Pharm Res* 11, 882 (1994); Ozturk et al, *J Controlled Release* 14, 203 (1990). Goodhart et al, *Pharmaceutical Tech* April, 64 (1984); Bodmeier and Paeratakul *Int J Pharmaceutics* 152, 17 (1997); Bodmeier and Paeratakul *Drug Develop Ind Pharmacy* 20, 1517 (1994)).

From these and other studies it can be concluded that one of the more interesting dispersions, due to the low T_g of the latex polymer and high elongation, is Eudragit® NE

30D, which contains approximately 28.5 % w/w particles of the copolymer poly(ethylacrylate - co-methylmethacrylate), and 1.5 % w/w of the non-ionic tenside Nonoxynol 100 (a polyoxyethylated nonylphenol) as a stabiliser. The advantages of this copolymer are that no plasticizer is needed for film formation, the copolymer has a low film forming temperature and the high flexibility of dried films. The last property is especially useful when preparing tablets. However, to obtain best spraying conditions and technical performance, an anti-sticking agent has to be added to the dispersion, as reported by Petereit and Weisbrod 1995, due to the tacky property of the pellets during coating. Several such agents are available e.g., talc, silica, magnesium stearate and glyceryl mono stearate (GMS). It was reported, however, that best performance of the dispersion during spraying and of the dried film was obtained when the GMS was dispersed with an extra surface active agent, e.g., Polysorbate 80 (PS80). The reason for adding PS80 is to be able to make a stabile dispersion between GMS and PS80 and to make a dispersion that has a small particle size distribution.

We have found that it has been difficult to obtain results with acceptable reproducibility with respect to, e.g., release rates and stability during storage from formulations manufactured according to these suggested procedures. It is important that the release profile is stable during the shelf life of the product and also stable in different environments.

Instabilities of coated dosage (water based) forms are mainly based on physical interaction caused, most likely, by improper formulations of coating suspension (i.e., plasticizers, surfactants, or pigments), or the film coating process (Petereit et al, Eur. J pharmaceuticals and Biopharmaceutics 47, (1999) 15-25). Residual moisture, probably enclosed in the core and, migrating over time, may increase the permeability of coatings due to plasticizing effects. This increased permeability can also be due to migration of components in the film coat during storage in different climates, thus resulting in a coating which exhibits altered release properties

Eur J Pharm Biopharm 41 (4) (1995) 219-228 by Petereit et al discloses the use of GMS as a glidant in aqueous film coating formulations comprising Eudragit® L 30 D-55, NE 30D, RL 30 D and RS 30 D.

5 Eur J Pharm Biopharm 47 (1999) 73-78 by Wesseling et al discusses how reduced tackiness of NE30D films is obtained by the addition of an anti-tacking agent, e g GMS. This is achieved by the addition of GMS in an emulsion form that is obtained by mixing a surfactant (e g Tween 80) with the GMS.

10 Eur J Pharm Biopharm 1999, 14 (6) p743-751 by Petereit, Weisbrod is a review article that gives compositions of dispersions for film formation in tables. However, nothing is said about how the additives, e g anti-tacking agents, are added.

AAPS Pharmasci 2001 3(2) 1-11 by Lin et al discloses that the endogenous surfactant of
15 NE30D, nonoxynol 100, crystallizes in films of NE30D. The importance of compensating for this tendency for crystallization is discussed.

J Microencapsulation 1997, vol 14, no 6, p743-751 by Mathir et al discloses coatings comprising NE30D, talc and PEG 6000 .

20 US 5, 817, 776 discloses that a dispersion of lubricant/glidant is formed in water with the help of an "antifoam suspension".

US 5,478,573 discloses that mixtures of different dispersions are prepared and stabilized
25 with the surface active agent sodium lauryl sulfate. Also disclosed is a coating comprising magnesium stearate dispersed in water and added to a mixture of the two dispersions NE30D and Aquacoat™.

US 4,784,858 discloses that the anti-tacking agent talc is added together with a surfactant
30 (Tween 80) to Eudragit E30D.

WO 02058677 discloses coating formulations comprising sodium stearyl fumarate (PRUV®).

Purpose of the invention

5 The purpose of the present invention is to provide a new film coating system that does not have the above mentioned problems. Improved properties of the new film coating system are, for example, non-stickiness, high mechanical strength, reproducibility during processing, and stability of the film coating during storage.

Summary of the invention

10 We have surprisingly found a novel film coating composition which provides a latex dispersion suitable for coating pharmaceutical formulations wherein the film produced serves as a barrier giving close to constant release (zero-order) from the formulation. In addition, the physical properties of the film produced no processing problems, such as
15 aggregation of particles; the film exhibited high mechanical strength; and the film was stable exhibiting no change in release properties as a result of storage. Moreover, the film could be reproducibly made having these improved properties.

Accordingly, the invention features a film coating composition, a film coating, a
20 formulation including a pharmaceutically core comprising a pharmaceutically active agent (e.g., metoprolol) and a film coat. The invention further includes a process of making the coating and a process to prepare a formulation having the coating of the invention.

Detailed description of the invention

25 The present invention provides a film coating which, has the unexpected property of having a stable release profile following storage. Specifically, the present invention features a pharmaceutical composition which surprisingly has a low amount of surface active agent.

Accordingly, the invention provides a film coating composition suitable for use in coating pharmaceutical formulations comprising a dispersion which comprises:

- a) an acrylic polymer, which is Eudragit[®] NE30D
- b) an anti-sticking agent, which is glyceryl monostearate (GMS)
- 5 c) a surface active agent wherein the surface active agent is in an amount less than 1.3 % by weight of the dispersion, and
- d) a water-containing liquid,

wherein the dispersion does not contain a vinyl acetate polymer.

10 In another aspect, the invention provides a film coat covering a pharmaceutical core wherein the core includes a pharmacologically active ingredient and optionally one or more pharmaceutically acceptable excipients. The film coat includes an:

- a) an acrylic polymer; which is Eudragit[®] NE30D
- b) an anti-sticking agent; which is glyceryl monostearate (GMS) and
- 15 c) a surface active agent wherein the surface active agent is in the amount less than 5.4 % by weight of the weight of the film coat, and wherein the film coat has been deposited from a water-containing liquid and does not contain a vinyl acetate polymer. In one embodiment, the acrylic polymer can be an ethyl acrylate and/or methyl methacrylate copolymer, the anti-sticking agent can be glyceryl mono stearate (GMS), and the surface
- 20 active agent can be nonoxynol 100. Suitably the film coat has a thickness in the range of 1 to 100 micrometres, preferably in the range of 5 to 50 micrometres and more preferably in the range of 10 to 30 micrometres

The pharmacologically active ingredient can be provided in a plurality of beads, optionally

25 containing one or more pharmaceutically acceptable excipients, wherein each of the beads is coated with a film coat as defined above. Such film coated beads may be provided in sachets or formulated as a capsule, for example a hard gelatin capsule, or compressed to form tablets using known methods with the optional addition of other pharmaceutically acceptable additives. Coated beads to be compressed into a tablet are obtained by

30 conventional techniques known to those skilled in the art. Also, during this process suitable

other agents can be added. For example, during the tableting step suitable fillers, e.g., microcrystalline cellulose, talc, sodium stearyl fumarate, etc., can be utilised to give acceptable compression characteristics of the formulation, e.g., hardness of the tablet.

- 5 Optionally the beads may contain an insoluble core onto which the active ingredient has been deposited, for example, by spraying. Suitable materials for the inert core are silicon dioxide, glass or plastic resin particles. Suitable types of plastic material are pharmaceutically acceptable plastics such as polypropylene or polyethylene preferably polypropylene. Such insoluble cores have a size diameter in the range of 0.01-2mm,
10 preferably in the range of 0.05-0.5mm and more preferably in the range of 0.1-0.3mm.

In one embodiment, the ductility of the film can be in a range of 500-20000 J/m³. In another embodiment the ductility is in the range of 2500-20000 J/m³. In yet another embodiment the ductility is in the range of 10000-20000 J/m³.

15

In another aspect, the invention provides a pharmaceutical formulation which includes

- a) a pharmaceutical core comprising a pharmacologically active ingredient and optionally one or more pharmaceutically acceptable excipients, and
b) a film coat comprising:
20 i) an acrylic polymer, which is Eudragit[®] NE30D
ii) an anti-sticking agent, which is glyceryl monostearate (GMS)
iii) a surface active agent wherein the surface active agent is in the amount less than 5.4 % by weight of the weight of the film coat,
wherein the film coat has been deposited from a water-containing liquid and does not
25 contain a vinyl acetate polymer.

The pharmacologically active ingredient can be provided in a plurality of beads, optionally containing one or more pharmaceutically acceptable excipients, wherein each of the beads is coated with a film coat as defined above. Such film coated beads may be provided in
30 sachets or formulated as a capsule, for example a hard gelatin capsule, or compressed to

form tablets using known methods with the optional addition of other pharmaceutically acceptable additives. Coated beads to be compressed into a tablet are obtained by conventional techniques known to those skilled in the art. Also, during this process suitable other agents can be added. For example, during the tableting step suitable fillers, e.g.,
5 microcrystalline cellulose, talc, etc., can be utilised to give acceptable compression characteristics of the formulation, e.g., hardness of the tablet. Suitably the beads have a diameter in the range of 0.01-2mm, preferably in the range of 0.05-1.0mm and more preferably in the range of 0.1-0.7mm.

10 Optionally the beads may contain an insoluble core onto which the active ingredient has been deposited, for example, by spraying. Suitable materials for the inert core are silicon dioxide, glass or plastic resin particles. Suitable types of plastic material are pharmaceutically acceptable plastics such as polypropylene or polyethylene preferably polypropylene. Such insoluble cores have a size diameter in the range of 0.01-2mm,
15 preferably in the range of 0.05-0.5mm and more preferably in the range of 0.1-0.3mm.

In one embodiment, the ductility of the film can be in a range of 500-20000 J/m³. In another embodiment the ductility is in the range of 2500-20000 J/m³. In yet another embodiment the ductility is in the range of 10000-20000 J/m³.

20 In a more preferred aspect the present invention provides a modified release formulation wherein the pharmacologically active ingredient is released over a long period of time, for example longer than 3 hours in comparison to an immediate release tablet e.g., up to 24 hours, in comparison to an immediate release tablet. Preferably the pharmacologically
25 active ingredient is released from the formulation over 10 to 24 hours, for example over 18 to 22 hours.

Preferably the pharmacologically active ingredient has activity in the treatment of cardiovascular diseases. In particular, the pharmacologically active ingredient is a beta-blocking adrenergic agent such as metoprolol or a pharmaceutically acceptable salt thereof.

5 In yet another aspect the invention provides a modified release metoprolol formulation including:

- a) a metoprolol core comprising metoprolol or a pharmaceutically acceptable salt thereof and optionally one or more pharmaceutically acceptable excipients; and
- b) a film coat as defined above.

10

In a preferred aspect the core comprising metoprolol or a pharmaceutically acceptable salt thereof includes a plurality of beads which comprise metoprolol or a pharmaceutically acceptable salt thereof and optionally one or more pharmaceutically acceptable excipients wherein each of the beads is coated with a film-coat as defined above. Preferably, the
15 beads have an inert core as described previously.

20

Suitable pharmaceutically acceptable salts of metoprolol include the tartrate, succinate, fumarate or benzoate salts and especially the succinate salt. The S-enantiomer of metoprolol or a salt thereof, particularly the benzoate salt or the sorbate salt, may also be used.

Eudragit[®] NE30D is an ethyl acrylate/ methyl methacrylate copolymer in which the ethyl acrylate concentration is about 67mol%.

25 It was surprisingly found that the film coating of the present invention could be made with low amounts of surface active agents and that such a coating exhibited stability over time. The surface active agent (surfactant) can act as a stabilizer.

Suitably the amount of surface active agent used in a film coating dispersion is in the
30 amount less than 1.3 %, e.g., 1.0, 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, or 0.1%, by weight of

the dispersion. In one embodiment, the surface active agent is in a range from 0.001-1.0 % by weight of the dispersion. In another embodiment, the surface active agent is in a range from 0.01-0.8% by weight of the dispersion. In yet another embodiment, the surface active agent is in a range from 0.1-0.5% by weight of the dispersion.

5

Suitably the amount of surface active agent present in the film coat is less than 5.4% by weight of the weight of the film coat, e.g., less than 5.0, 4.5, 3.5, 3.0, 2.5, 2.0, 1.5, 1.0, 0.5, 0.1, 0.01, or 0.001% by weight of the weight of the film coat. In one embodiment, the surface active agent in the film coat is in a range from 0.01-5.0 % by weight of the weight of the film coat. In another embodiment, the surface active agent is in a range from 0.1-4.0% by weight of the weight of the film coat. In yet another embodiment, the surface active agent is in a range from 1.0-3.0% by weight of the weight of the film coat

10

Suitably the amount of surface active agent present in the dispersion is less than 5.6%, e.g., less than 5.0, 4.5, 3.5, 3.0, 2.5, 2.0, 1.5, 1.0, 0.5, 0.1, 0.01, or 0.001%, based on the dry weight of the film coating components.

15

Examples of suitable surface active agents\stabilizers include:

a nonionic surfactant, like sorbitan esters (Span series); polysorbates (Tween series); polyoxyethylated glycol monoethers (like the Brij series); polyoxyethylated alkyl phenols (like the Triton series or the Igepal series); alkyl glucosides (e.g., dodecylmaltoside); sugar fatty acid esters (e.g., sucrose laurate); saponins; etc: or mixtures thereof;

20

ampholytic surfactants, like betaines;

25

anionic surfactants, like sulphated fatty alcohols eg sodium dodecylsulphate SDS; sulphated polyoxyethylated alcohols; others like dioctyl sulphosuccinate; bile salts (e.g., dihydroxy bile salts like sodium deoxycholate, trihydroxy bile salts like sodium glycocholate, etc); fusidates (e.g., sodium dihydrofusidate); etc

30

cationic surfactants, like ammonium compounds;

soaps, fatty acids, and lipids and their salts, like alcanoic acids; (e.g., octanoic acid, oleic acid); monoglycerides (eg monolein), phospholipids which are neutral or positively or
5 negatively charged (eg dialkyl phosphatidylcholine, dialkyl phosphatidylserine, etc).

More preferably the surface active agent is a nonionic surfactant. Most preferably the surface active agent is nonoxynol 100.

10 Optionally, other different excipients can be included in the formulation by methods known to those skilled in the art, such as lubricants, plasticizers, etc.

Suitably the water-containing liquid comprises water and a water miscible organic liquid for example lower alkanols e.g. ethanol, propanol or isopropanol. From a safety point of
15 view it is preferred that the proportion of the organic is kept to a minimum but small amounts are tolerable for example in the range of 0 to 20 % by volume. Preferably the liquid is water.

The film-coating composition is particularly suitable for use as an aqueous film-coating
20 composition wherein the film-coat is applied using water as the liquid. This process is particularly advantageous as it negates the need to use environmentally unacceptable organic solvents, some of which also present processing problems due to their inflammability, while also eliminating many of the problems experienced with aqueous coatings described above.

25

In another aspect the present invention provides processes for the preparation of the film-coating composition. Therefore, there is provided a process for the preparation of a film-coating composition comprising mixing together the acrylic polymer dispersion, vinyl acetate polymer dispersion, the stabilizer and the liquid at a temperature in the range of 10
30 to 100°C.

In one embodiment of the process the acrylic polymer dispersion, the stabilizer, the surface active agent and the liquid, are mixed at room temperature.

- 5 Suitably mixing is achieved by methods such as stirring or shaking but other methods of homogenization known to those skilled in the art may be used.

In another aspect the present invention provides a process for film coating a pharmaceutical core wherein a film coating composition as defined above is applied to a
10 core. Preferably the film coating composition is applied by spraying for example in a fluidised bed with top spray or bottom spray techniques. Other coating methods used are coating in standard coating pans with perforated pans, Accela-cota, immersion swords, Glatt, or immersion tubes as described in "Theory and Practice in Industrial Pharmacy" edited by Lachman , published by Lea and Feabiger 1986 3rd edition.

15

In another aspect the invention provides a process to prepare a film coat as defined above comprising removing the liquid from a film coating composition as defined above. Suitably the liquid is removed by evaporation for example by spray drying for example in a fluidised bed.

20

In yet another aspect the invention provides a process to prepare a formulation as defined above comprising coating a pharmaceutical core as defined above with a film coating composition as defined above.

- 25 In a further aspect the invention provides a process to prepare a formulation in which the pharmacologically active ingredient is provided as a plurality of beads as defined above comprising coating the plurality of beads with a film-coating composition as defined above.

Examples

The following examples are non-limiting and are given by way of illustration only. It will be appreciated by those skilled in the art that the examples are to be looked upon as
5 guidelines, and the invention is not restricted to the exemplified compositions. A wide range of combinations is possible to give film coatings having the necessary properties required for each specific application.

Example 1:

10 *Preparation of coated metoprolol succinate pellets from NE30D/GMS/PS80. The preparation contains:*

*5,0g GMS + 190g water + 1g Polysorbate80 + 25g cold water + 334,6g NE 30D
(giving GMS/particle ratio approximately 5% and PS80/GMS ratio approximately 20%)*

15 The mixture of 5g GMS, 1g Polysorbate 80 and 190g water was heated to 60-63°C while stirring. After 30 minutes (min) of homogenizing, the mixture was cooled initially by adding 25g cold water and then further cooled in a cold-water bath until the temperature was below 35°C. The solution was then slowly poured into the NE30D dispersion while
20 gently stirring. Stirring was continued until the start of coating.

The coating was performed in a small-scale coater. Coating was performed by pouring 400g of metoprolol succinate pellets (size fraction 0.40-0.63 mm, with inert silicon dioxide cores) into the coater and the solution sprayed on to it. The coated pellets were cured
25 afterwards in a 60°C heat cabinet for one (1) hour.

The coating yield was 92%. The drug content for the pellets after coating: 630mg/g pellets. The coated pellets were then analysed regarding drug content and release profile.

Dissolution tests were conducted in USP 23 paddle apparatus equipped with flow -through cells (at 37°C, 100 rpm, 500ml sodium phosphate buffer solution, pH 6,8). The release from the coated pellets and tablets was measured online using an UV- spectrophotometer (Lambda 2, Perkin-Elmer) at 274nm. The amount of drug release was calculated on the
 5 determined drug content.

Table 1

Release time (h)	Zero value	7 days in climate 1	7 days in climate 2	7 days in climate 3	14 days in climate 1	14 days in climate 2	14 days in climate 3
1	0,3	0,3	0,4	0,5	0,3	0,3	0,4
2	0,4	0,3	0,4	0,6	0,3	0,3	0,5
3	0,4	0,4	0,5	0,7	0,4	0,4	0,6
4	0,4	0,4	0,5	0,87	0,4	0,5	0,9
6	0,5	0,6	0,8	2,4	0,5	0,8	4,1
8	0,6	1,0	1,7	6,9	0,9	2,3	11,4
10	1,2	2,1	4,4	13,5	2,3	6,9	20,6
12	2,6	5,9	13,6	21,4	7,7	19,6	30,5
14	8,2	19,8	35,4	30,1	26,6	42,4	40,8
16	23,6	44,7	58,4	39,6	52,9	62,3	51,1
18	44,3	64,8	72,7	49,4	70,4	75,1	60,9
20	61,1	76,2	81,2	58,6	80,1	82,7	69,2

Zero value: release value after curing (60°C/ 50% relatively humidity (r.h.) during 60 min). Climate 1; 25°C/ 60% r.h. Climate 2; 30°C/60%r.h. Climate 3; 40°C/75%r.h. Each value is a mean value of two analyses.

10

Results

The results show how the release profiles change with time and storage conditions. Samples stored in higher temperatures and humidity tended to have a more linear profile compared to those samples in lower temperatures and humidity. This change during

storage is most likely due to migration of surfactants, especially polysorbate 80, up to surface leading to increased permeability.

Example 2:

- 5 *Preparation of coated metoprolol succinate pellets from NE30D/GMS solution. The preparation contains:*

3,0g GMS + 150g water + 25g cold water + 200g NE 30D

(giving GMS/particle ratio approximately 5% and film amount/pellets ratio approximately 20%)

10

The mixture of 3g GMS and 150g water was heated to 60-63°C while stirring. After 30 minutes the mixture was cooled initially by adding 25g cold water and then further cooled in a cold-water bath until the temperature was below 35°C. The solution was then slowly poured into the NE30D dispersion while gently stirring. Stirring was continued until the
15 start of coating.

The coating was performed in a small-scale coater. Coating was performed by pouring 350g of metoprolol succinate pellets(size fraction 0.40-0.63 mm, with inert silicon dioxide cores) into the coater and the solution sprayed on to it. The pellets where cured afterwards
20 in a 60°C heat cabinet for 6 min. The coating yield was 90%. The drug content for the pellets after coating: 659mg/g pellets.

The coated pellets were then stored in a climate cabin at different temperatures and humidity for one and two weeks. The coated pellets where then analysed regarding drug
25 content and release profile.

Dissolution tests were conducted in USP 23 paddle apparatus equipped with flow -through cells (at 37°C, 100 rpm, 500ml sodium phosphate buffer solution, pH 6.8). The release from the coated pellets and tablets was measured online using an UV- spectrophotometer

(Lambda 2, Perkin-Elmer) at 274nm. The amount of drug release was calculated on the determined drug content.

Results

- 5 The release profile was analysed for the coated pellets after final drying (curing) and after 7 and 14 days in three different climates, see table 2.

Table 2

Release Time (h)	Zero value	7days in climate 1	7days in climate 2	7 days in climate 3	14 days in climate 1	14 days in climate 2	14 days in climate 3
1	0,49	0,3	0,3	0,2	0,3	0,2	0,3
2	1,6	0,76	0,5	0,3	0,68	0,3	0,6
3	3,7	1,9	1,1	0,4	1,4	0,7	0,8
4	6,98	3,9	2,3	0,7	2,8	1,6	1,2
6	17,4	13,3	10,4	3,5	10,9	9,4	3,7
8	27,9	25,5	24,8	13,85	24,1	25	13
10	37,6	36,1	37,2	27,6	35,4	38,3	25,8
12	47,2	46,1	48,3	40,5	45,8	49,9	38,6
14	56,5	55,7	58,5	52,35	55,6	60,4	50,4
16	65,1	64,55	67,3	62,2	64,6	69,1	60,4
18	72,5	72,4	74,6	69,8	72,1	75,7	68,1
20	78,3	77,8	80,2	75,4	78,1	80,8	74

Climate 1; 25°C/ 60% r.h. Climate 2; 30°C/60%r.h. Climate 3; 40°C/75%r.h.

- 10 Each value is a mean value of two analysis.

Results

The results shows similar profiles after 7 and 14 days in the three different climates. No migration can be seen in Example 2.

Example 3 Tablets made from the coated pellets of Example 2*Preparation of 950 tablets*

The coated pellets were compressed into tablets by conventional techniques. During this process other agents were added, fillers Avicel and Sodium stearyl fumarate (Pruv®) to give acceptable compression characteristics of the formulation, e.g. hardness and weight.

136,9g of coated pellets (from experiment 2) were mixed with 205,3g of microcrystalline cellulose (Avicel PH 102 (course), FMC) in a Turbula mixer (W.A. Bachofen, Switzerland) for 4 minutes. After this time 0,68g Sodium stearyl fumarate was added and mixing was continued for another minute. The tablet weight was calculated to be 361 mg.

Tablets of pellets were compacted in a rotary tablet machine (six (6) punch press, Korch PH 106, Germany). The press was equipped with concave-faced punches with a diameter of 10mm. The force used was approximately 4 KN. The hardness of the tablets were approx. 142 N (mean value of ten measurements). After the tablets have been sorted out by weight, they were put in the same cabin as the coated pellets from Example 2, and samples were taken after one and four weeks. See Table 3.

The release profile of the tablets was then analysed.

Dissolution tests were conducted in USP 23 paddle apparatus equipped with flow-through cells (at 37°C, 100 rpm, 500ml sodium phosphate buffer solution, pH 6,8). The release from the coated pellets and tablets was measured online using an UV-spectrophotometer (Lambda 2, Perkin-Elmer) at 274nm. The amount of drug release was calculated on the determined drug content.

Table 3

Release Time (h)	Zero value	7days in climate 1	7days in climate 2	7 days in climate 3	28 days in climate 1	28 days in climate 2	28 days in climate 3
1	15	19	19	13	19	18	17
2	27	34	34	29	35	32	32
3	37	44	43	41	45	42	43
4	45	52	51	49	52	50	51
6	58	62	61	60	63	61	62
8	67	70	69	68	71	70	69
10	74	77	75	74	77	76	75
12	79	82	80	79	83	82	79
14	84	87	85	84	87	87	83
16	87	91	89	87	91	90	86
18	90	94	92	90	93	93	89
20	93	97	94	93	95	96	91

Each value is a mean value of two analysis.

Climate 1; 25°C/ 60% r.h. Climate 2; 30°C/60%r.h. Climate 3; 40°C/75%r.h.

5

Results

The results showed no major change in the release profile during storage in the different climates.

10

Claims

1. A film coating composition suitable for use in coating pharmaceutical formulations comprising a dispersion comprising:

- a) an acrylic polymer, which is Eudragit[®] NE30D
- 5 b) an anti-sticking agent, which is glyceryl monostearate (GMS)
- c) a surface active agent wherein the surface active agent is in an amount less than 1.3 % by weight of the dispersion, and
- d) a water-containing liquid,

wherein the dispersion does not contain a vinyl acetate polymer.

10 2. A film coat covering a pharmaceutical core wherein the core comprises a pharmacologically active ingredient and optionally one or more pharmaceutically acceptable excipients wherein the film coat comprises:

- a) an acrylic polymer, which is Eudragit[®] NE30D
- 15 b) an anti-sticking agent, which is glyceryl monostearate (GMS)
- c) a surface active agent, wherein the surface active agent is in the amount less than 5.4 % by weight of the weight of the film coat,

wherein the film coat has been deposited from a water-containing liquid and does not contain a vinyl acetate polymer.

20 3. A pharmaceutical formulation comprising:

- a) a pharmaceutical core comprising a pharmacologically active ingredient and optionally one or more pharmaceutically acceptable excipients, and
- b) a film coat comprising:
 - 25 i) an acrylic polymer, which is Eudragit[®] NE30D
 - ii) an anti-sticking agent, which is glyceryl monostearate (GMS) , and
 - iii) a surface active agent, wherein the surface active agent is in the amount less than 5.4 % by weight of the weight of the film coat,

wherein the film coat has been deposited from a water-containing liquid and does not

30 contain a vinyl acetate polymer.

4. A pharmaceutical formulation comprising a pharmacologically active ingredient which is provided in a plurality of beads which optionally contain one or more pharmaceutically acceptable excipients wherein each of the beads is coated with a film coat as defined in claim 2.

5. A formulation according to either claims 3 or 4 wherein the formulation is a modified release formulation.

6. A formulation according to any one of claims 3, 4 or 5 wherein the pharmacologically active ingredient has activity in the treatment of cardiovascular diseases.

7. A formulation according to claim 6 in which the pharmacologically active ingredient is a beta-blocking adrenergic agent.

8. A formulation according to claim 7 in which the pharmacologically active ingredient is metoprolol or a pharmaceutically acceptable salt thereof.

9. A formulation according to claim 8 in which the metoprolol salt is a tartrate, succinate, fumarate or benzoate salt .

10. A composition as claimed in claim 1 wherein the liquid is water.

11. A process for the preparation of a film coating composition according to claim 1 comprising mixing together the acrylic polymer dispersion, the anti-sticking agent, the surface active agent, and the liquid at a temperature in the range of 10 to 100°C.

12. A process to prepare a formulation as claimed in claims 3 to 9 comprising coating the pharmaceutical core with a film coating composition as defined in claim 1.

13. A process to prepare a formulation as claimed in claims 3 to 9 comprising coating the plurality of beads with a film coating composition as defined in claim 1.

INTERNATIONAL SEARCH REPORT

Internati Application No

PCT/GB 03/03195

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A61K9/50 A61K9/20

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, EMBASE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PETEREIT H-U ET AL: "GLYCERYL MONOSTEARATE AS A GLIDANT IN AQUEOUS FILM-COATING FORMULATIONS" EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 41, no. 4, 1 August 1995 (1995-08-01), pages 219-228, XP000521040 ISSN: 0939-6411 the whole document example 11; table 4 ---	1-3,5, 10-12
X	EP 0 403 959 A (ROEHM GMBH) 27 December 1990 (1990-12-27) claim 1; example 1 --- -/-	1-3,5, 10-12



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

° Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

* & * document member of the same patent family

Date of the actual completion of the international search

20 November 2003

Date of mailing of the international search report

19/12/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

ESTANOL, I

INTERNATIONAL SEARCH REPORT

Internal Application No

PCT/GB 03/03195

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>PETEREIT H-U ET AL: "Formulation and process considerations affecting the stability of solid dosage forms formulated with methacrylate copolymers"</p> <p>EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 47, no. 1, January 1999 (1999-01), pages 15-25, XP004257023</p> <p>ISSN: 0939-6411</p> <p>the whole document</p> <p>page 23 -page 24; table 3</p> <p>---</p>	1-3
A	<p>WESSELING M ET AL: "Tackiness of acrylic and cellulosic polymer films used in the coating of solid dosage forms"</p> <p>EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 47, no. 1, January 1999 (1999-01), pages 73-78, XP004257029</p> <p>ISSN: 0939-6411</p> <p>the whole document</p> <p>---</p>	1-13
P,X	<p>WO 02 058677 A (LOEFROTH JAN-ERIK ;ASTRAZENECA AB (SE); HOELZER ARNE (SE); SCHANTZ) 1 August 2002 (2002-08-01)</p> <p>examples COMP.,1</p> <p>---</p>	1-3,5, 10-12
P,A	<p>WO 03 051340 A (ASTRAZENECA UK LTD ;ASTRAZENECA AB (SE); SCHANTZ STAFFAN (SE); WEL) 26 June 2003 (2003-06-26)</p> <p>claims 1-22; examples 1-10</p> <p>-----</p>	1-13

INTERNATIONAL SEARCH REPORT

ation on patent family members

Internat Application No

PCT/GB 03/03195

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0403959	A	27-12-1990	DE 3920082 A1	07-03-1991
			AT 93386 T	15-09-1993
			DD 295086 A5	24-10-1991
			DE 59002445 D1	30-09-1993
			EP 0403959 A1	27-12-1990
			HU 64865 A2	28-03-1994
			JP 2960482 B2	06-10-1999
			JP 3031218 A	12-02-1991
			US 5292522 A	08-03-1994
WO 02058677	A	01-08-2002	CA 2433530 A1	01-08-2002
			EP 1355635 A1	29-10-2003
			NO 20033305 A	22-07-2003
			WO 02058677 A1	01-08-2002
WO 03051340	A	26-06-2003	CA 2435729 A1	26-06-2003
			CZ 20031970 A3	15-10-2003
			EP 1355633 A1	29-10-2003
			WO 03051340 A1	26-06-2003